A detailed history of Two Sigma Investments, LP transactions in Glycomimetics Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 44,646 shares of GLYC stock, worth $10,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,646
Holding current value
$10,268
% of portfolio
0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.16 - $0.32 $7,143 - $14,286
44,646 New
44,646 $7,000
Q4 2023

Feb 14, 2024

SELL
$1.13 - $2.54 $61,529 - $138,305
-54,451 Reduced 47.73%
59,621 $140,000
Q3 2023

Nov 14, 2023

SELL
$1.29 - $1.73 $97,596 - $130,884
-75,656 Reduced 39.88%
114,072 $171,000
Q2 2023

Aug 14, 2023

SELL
$1.21 - $2.08 $218,817 - $376,149
-180,841 Reduced 48.8%
189,728 $330,000
Q1 2023

May 15, 2023

BUY
$1.25 - $4.05 $190,257 - $616,434
152,206 Added 69.7%
370,569 $466,000
Q4 2022

Feb 14, 2023

SELL
$0.57 - $3.03 $5,665 - $30,118
-9,940 Reduced 4.35%
218,363 $661,000
Q3 2022

Nov 14, 2022

SELL
$0.55 - $0.9 $51,689 - $84,582
-93,980 Reduced 29.16%
228,303 $126,000
Q2 2022

Aug 15, 2022

SELL
$0.54 - $1.15 $53,209 - $113,316
-98,536 Reduced 23.42%
322,283 $193,000
Q1 2022

May 16, 2022

SELL
$1.0 - $1.58 $189,443 - $299,319
-189,443 Reduced 31.04%
420,819 $480,000
Q4 2021

Feb 14, 2022

BUY
$1.44 - $2.14 $160,894 - $239,106
111,732 Added 22.41%
610,262 $879,000
Q3 2021

Nov 15, 2021

BUY
$1.8 - $2.39 $491,275 - $652,305
272,931 Added 120.98%
498,530 $1.09 Million
Q2 2021

Aug 16, 2021

SELL
$2.16 - $3.18 $1.38 Million - $2.04 Million
-640,652 Reduced 73.96%
225,599 $523,000
Q1 2021

May 17, 2021

BUY
$2.89 - $4.22 $262,822 - $383,775
90,942 Added 11.73%
866,251 $2.61 Million
Q4 2020

Feb 16, 2021

BUY
$2.69 - $4.24 $1.26 Million - $1.99 Million
468,701 Added 152.87%
775,309 $2.92 Million
Q3 2020

Nov 16, 2020

SELL
$3.07 - $5.0 $510,884 - $832,060
-166,412 Reduced 35.18%
306,608 $941,000
Q2 2020

Aug 14, 2020

BUY
$2.06 - $3.76 $406,427 - $741,829
197,295 Added 71.55%
473,020 $1.78 Million
Q1 2020

May 15, 2020

BUY
$1.83 - $5.41 $137,076 - $405,236
74,905 Added 37.3%
275,725 $629,000
Q4 2019

Feb 14, 2020

BUY
$4.03 - $6.5 $309,532 - $499,245
76,807 Added 61.93%
200,820 $1.06 Million
Q3 2019

Nov 14, 2019

BUY
$2.8 - $12.85 $347,236 - $1.59 Million
124,013 New
124,013 $534,000
Q1 2019

May 15, 2019

SELL
$9.96 - $13.44 $159,907 - $215,779
-16,055 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$8.47 - $14.71 $135,985 - $236,169
16,055 New
16,055 $152,000
Q1 2018

May 15, 2018

SELL
$16.06 - $25.35 $367,565 - $580,185
-22,887 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$10.51 - $17.22 $240,542 - $394,114
22,887
22,887 $384,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $12.1M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.